Ukuvunyelwa kwe-HIBRUKA (Orelabrutinib) yokwelapha i-Marginal Zone Lymphoma eSingapore

8 Septhemba 2025, i-InnoCare Pharma imemezele ukuthi i-HIBRUKA (orelabrutinib) ivunyelwe yi-Health Sciences Authority (HSA) yaseSingapore ekwelapheni iziguli ezindala ezine-relapse noma i-refractory marginal zone lymphoma (R/R MZL).

Njengamanje, kusenezivivinyo eziningi zemitholampilo zobuchwepheshe obusha bokulwa nomdlavuza eShayina ezifuna iziguli. Ukubonisana ngemithi emisha kanye nobuchwepheshe, ungaxhumana noMnyango Wezizwe Ngezizwe Wesibhedlela iBeijing South Region Oncology.

Inombolo yocingo: 4008803716

I-ID ye-WeChat: 17801183037

Email：myimmnet@163.com

I-Marginal zone lymphoma (MZL) iyi-lymphoma ye-B-cell engesiyo i-Hodgkin's (NHL) engasebenzi kahle ethinta kakhulu iziguli ezineminyaka ephakathi nendawo kanye nabantu asebekhulile. Inani laminyaka yonke le-MZL liyakhula emhlabeni jikelele. Ngemva kokwelashwa kokuqala, iziguli ezine-R/R MZL azinazo izinketho zokwelapha ezisebenzayo.

Ngo-Ephreli 2025, i-orelabrutinib yathola imvume eShayina yokwelashwa kokuqala kweziguli ezine-chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL). I-Orelabrutinib nayo ivunyelwe ukwelashwa kwezinye izinkomba ezintathu eShayina, okuhlanganisa i-relapse and refractory (R/R) CLL/SLL, r/r mantle cell lymphoma (R/R MCL) kanye ne-r/r marginal zone lymphoma (R/R MZL) yaseShayina, konke okuhlanganiswe ohlwini lwezidakamizwa zokubuyiselwa kwemali kazwelonke.

Ukusebenza, Ukuphepha, kanye Nokuqonda kwe-Orelabrutinib Plus Obinutuzumab ku-Systemic Treatment-Naive Marginal Zone Lymphoma: Ucwaningo Lweqembu Elilindelekile lubonise ukuthi Kuyo yonke le sifundo kanye nangesikhathi sokwelashwa ngokungeniswa, izinga lokuphendula eliphelele (ORR) lingu-100%. Iziguli ezintathu ezinempendulo engaphelele (PR) ngemuva kokwelashwa ngokungeniswa zithole impendulo ephelele (CR) ngesikhathi sokulungiswa.

Ukuhlolwa kwe-ADCC kubonise ukuthi i-orelabrutinib ihlanganiswe nohlelo lwe-obinutuzumab ibangele impendulo ye-ADCC esebenzayo kakhulu emigqeni yamaseli e-TMD-8 kanye ne-REC-1.

Njengamanje, kusenezivivinyo eziningi zemitholampilo zobuchwepheshe obusha bokulwa nomdlavuza eShayina ezifuna iziguli. Ukubonisana ngemithi emisha kanye nobuchwepheshe, ungaxhumana noMnyango Wezizwe Ngezizwe Wesibhedlela iBeijing South Region Oncology.

Inombolo yocingo: 4008803716

I-ID ye-WeChat: 17801183037

Email：myimmnet@163.com